Beta Bionics has announced the pricing of its upsized initial public offering of 12 million shares of common stock at a price to the public of $17 per share.

BofA Securities, Piper Sandler, and Leerink Partners acted as lead bookrunners for the offering. Stifel acted as a bookrunner and Lake Street Capital Markets acted as co-manager for the offering.

Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, today announced the pricing of its upsized initial public offering of 12,000,000 shares of common ...

Thursday marked the Nasdaq Global Market debut of Beta Bionics, Inc. as its initial public offering (IPO) opened for trading ...

Achieving a staggering $15 million valuation before even launching its beta app, LisBon has emerged as a symbol of transformative potential—not just for Nigeria, but for Africa and the global tech ...

A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

The ProShares Ultra Ether ETF offers 2x daily returns on Ethereum trading, ideal for short-term bets. Click here to find out why ETHT ETF is a Hold.

Mawson Infrastructure Group Inc. (NASDAQ:MIGI), a company specializing in finance services under the organization name 09 Crypto Assets, has been notified by The Nasdaq Stock Market LLC of its ...

Annaly Capital Management's potential benefit from lower interest rates in 2025, but the impact of inflation and central bank ...

When is the Elden Ring Nightreign beta? The Lands Between beckons us once more for a standalone co-op adventure that introduces a roguelike loop into FromSoftware’s formula. Playtests are the ...